Merck KGaA Signs Licensing Agreement with Debiopharm for Xevinapant
March 01 2021 - 6:43AM
Dow Jones News
By Giulia Petroni
Merck KGaA said Monday that it has signed an in-licensing
agreement with biopharmaceutical company Debiopharm for the
development and commercialization of xevinapant.
The German pharmaceuticals and chemicals company said it will
have exclusive development and commercialization rights, while
Debiopharm will receive 188 million euros ($226.9 million) in
upfront payments and up to EUR710 million in regulatory and
commercial milestones, as well as royalty payments.
The transaction is expected to be closed early in the second
quarter.
Xevinapant is an oral inhibitor of apoptosis proteins antagonist
for locally advanced squamous cell carcinoma of the head and neck
in combination with current standard of care, according to Merck
KGaA. It is currently being investigated in the phase-III TrilynX
study, which the companies will now co-fund.
Earlier this year, xevinapant received breakthrough therapy
designation by the U.S. Food and Drug Administration.
Write to Giulia Petroni at giulia.petroni@wsj.com
(END) Dow Jones Newswires
March 01, 2021 06:28 ET (11:28 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Apr 2023 to Apr 2024